Navigation Links
Hemaclear Announces First Annual Italian Distributor and User Conference: May 22, 2013 in Rome, Italy

Haifa, Israel (PRWEB) May 15, 2013

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it will hold its first annual Italian distributor and user conference; May 22, 2013 in Rome, Italy. The conference will be the first time Hemaclear users and distributors from Italy will meet to discuss the competitive and clinical advantage of the novel tourniquet.

Since the launch of Hemaclear in 2008 in Italy, the novel tourniquet has quickly become the standard of care at many Italian hospitals and clinics. Over the past 5 years regional distributors have recognized the positive business contributions of the device, while surgeons have recognized the positive clinical contributions. In a country where reusable pneumatic tourniquets were the standard of care prior to the launch of Hemaclear, physicians and patients can now experience the benefits of a reliable, safe, and sterile tourniquet.

“We are very excited to have the opportunity to meet with our distributor partners and surgeon users in Rome. This conference will provide all an opportunity to learn, network, and further discuss our commercialization efforts in Italy,” said Omer Inbar, CEO, OHK Medical Devices. Mr. Inbar added, “After a very strong year in 2012, we hope to continue the positive momentum in Italy. We strive to increase our Italian distribution network, and surgeon user base.”

OHK Medical Devices will be hosting the meeting May 22, 2013 at the Sofitel Rome Villa Borghese. To schedule a meeting or learn more about the conference please email info(at)hemaclear(dot)com.

About HemaClear®

HemaClear® is the world’s leading sterile tourniquet with a simple yet innovative technology, representing a new standard of care in bloodless orthopedic surgery. Since entering the market in 2007 this product has been successfully used in almost 500,000 procedures. Easier, cheaper and safer than the standard offerings, HemaClear® represents the first significant advancement in tourniquet technology in over 100 years. HemaClear® was developed by OHK Medical Devices (OHK), a privately held company based in Haifa, Israel and the United States and is currently used in over 2000 operating rooms across 30 countries. For more information about HemaClear®, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. HemaClear Launches Activity in APAC
2. IntraMed Diagnostics Announces Two Senior-Level Additions
3. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
4. Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
5. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
6. Winding River Productions Announces High-End Studio Enhancements Including SCORM-Compliant e-Learning Media Development and On-Location Data and Media Capture Platforms
7. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
8. Yongye International Announces First Quarter 2013 Financial Results
9. Vestiage Announces Initial Advisory Board Members
10. PDL BioPharma Announces First Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
(Date:11/24/2015)... Switzerland (PRWEB) , ... November 24, 2015 , ... ... plant and the environment are paramount. Insertion points for in-line sensors can represent ... has developed the InTrac 781/784 series of retractable sensor housings , which ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/23/2015)... , Nov. 24, 2015 Women with a ... CT exams face a higher risk of lung cancer than ... presented next week at the annual meeting of the Radiological ... --> --> Lung nodules ... classified as solid or subsolid based on their appearance on ...
(Date:11/23/2015)... The royalty-free a greement a llows ... 112 low- and m iddle-i ncome ... --> The Medicines Patent Pool (MPP) today announced its ... with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral that ... virus.  The royalty-free licence will enable generic manufacture of daclatasvir ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
Breaking Biology News(10 mins):